Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis (CENTAUR)
CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis
Sponsor: Tobira Therapeutics, Inc.
A PHASE2 clinical study on Nonalcoholic Steatohepatitis, this trial is completed. The trial is conducted by Tobira Therapeutics, Inc. and has accumulated 10 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tobira Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Adelaide, Australia , Alicante, Spain , Angers, France , Ann Arbor, United States , Baltimore, United States , Barcelona, Spain , Bedford Park, Australia , Berlin, Germany , Bologna, Italy and 71 more locations